127 related articles for article (PubMed ID: 20660828)
1. Causal inference for definitive clinical end points in a randomized clinical trial with intervening nonrandomized treatments.
Korn EL; Freidlin B
J Clin Oncol; 2010 Aug; 28(24):3800-2. PubMed ID: 20660828
[No Abstract] [Full Text] [Related]
2. Times to event: why are they hard to visualize?
Wittes J
J Natl Cancer Inst; 2008 Jan; 100(2):80-1. PubMed ID: 18182615
[No Abstract] [Full Text] [Related]
3. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trials: misleading and unreliable.
Stewart DJ
J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
[No Abstract] [Full Text] [Related]
5. [Treatment results of neuroblastoma in children in the Republic of Belarus].
Proleskovskaia IV; Savich TV; Mareĭko IuE; Savva NN; Aleĭnikova OV
Vopr Onkol; 2009; 55(2):215-20. PubMed ID: 19514379
[TBL] [Abstract][Full Text] [Related]
6. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
[No Abstract] [Full Text] [Related]
7. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation?
Willemze R; Labar B
Semin Hematol; 2007 Oct; 44(4):267-73. PubMed ID: 17961726
[TBL] [Abstract][Full Text] [Related]
8. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
9. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
10. Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia.
Herbst C; Monsef I; Skötz N; Engert A;
J Natl Cancer Inst; 2008 Aug; 100(15):E1. PubMed ID: 18664654
[No Abstract] [Full Text] [Related]
11. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
12. [Current strategies in the treatment of advanced stage mantle cell lymphoma].
Lenz G; Dreyling M; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ;
Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571
[TBL] [Abstract][Full Text] [Related]
14. Nonrandomized quality improvement intervention trials might overstate the strength of causal inference of their findings.
Li LC; Moja L; Romero A; Sayre EC; Grimshaw JM
J Clin Epidemiol; 2009 Sep; 62(9):959-66. PubMed ID: 19211223
[TBL] [Abstract][Full Text] [Related]
15. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.
Cavo M; Terragna C; Renzulli M; Zamagni E; Tosi P; Testoni N; Nicci C; Cangini D; Tacchetti P; Grafone T; Cellini C; Ceccolini M; Perrone G; Martinelli G; Baccarani M; Guardigni L
J Clin Oncol; 2006 Jan; 24(3):e4-5. PubMed ID: 16421414
[No Abstract] [Full Text] [Related]
16. Re: The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials.
Shrier I
Stat Med; 2008 Jun; 27(14):2740-1; author reply 2741-2. PubMed ID: 18069729
[No Abstract] [Full Text] [Related]
17. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
18. Criticism of tumor response criteria raises trial design questions.
Twombly R
J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
[No Abstract] [Full Text] [Related]
19. Adaptive biased-coin designs for skewing the allocation proportion in clinical trials with normal responses.
Atkinson AC; Biswas A
Stat Med; 2005 Aug; 24(16):2477-92. PubMed ID: 16007571
[TBL] [Abstract][Full Text] [Related]
20. Evidence from nonrandomized studies: a case study on the estimation of causal effects.
Schmoor C; Caputo A; Schumacher M
Am J Epidemiol; 2008 May; 167(9):1120-9. PubMed ID: 18334500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
